US equities
|
MU
$1,037.39
▼-4.65%
NVDA
$230.49
▼-2.94%
SNDK
$1,606.70
▼-5.06%
AMD
$618.65
▼-4.21%
INTC
$106.10
▼-6.21%
SPCX
$162.16
▼-3.25%
META
$716.88
▼-0.61%
PLTR
$196.20
▲+1.07%
MU
$1,037.39
▼-4.65%
NVDA
$230.49
▼-2.94%
SNDK
$1,606.70
▼-5.06%
AMD
$618.65
▼-4.21%
INTC
$106.10
▼-6.21%
SPCX
$162.16
▼-3.25%
META
$716.88
▼-0.61%
PLTR
$196.20
▲+1.07%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
22.11
+0.18 (+0.82%)
Delayed Quote
Updated: 2:04 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Collegium Pharmaceutical, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
May 11, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...
Via
StockStory
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results
May 08, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) announced better-than-expected revenue in Q1 CY2026, with sales up 8.9% year on year to $193.5 ...
Via
StockStory
Collegium (COLL) Q1 2026 Earnings Transcript
↗
May 07, 2026
Collegium (COLL) Q1 2026 Earnings Transcript
Via
The Motley Fool
Collegium Pharmaceutical (NASDAQ:COLL) Surges on Q1 Earnings Beat as JORNAY PM Revenue Jumps 36%
↗
May 07, 2026
Via
Chartmill
Topics
Earnings
Collegium Pharmaceutical Inc (NASDAQ:COLL) Priced for a Value Rebound
↗
May 05, 2026
Via
Chartmill
Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case
↗
March 28, 2026
Via
Chartmill
Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Q4 Revenue Growth but Misses Earnings Estimates
↗
February 26, 2026
Via
Chartmill
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars
May 07, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 8.9% year o...
Via
StockStory
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
May 07, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For
May 05, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors sho...
Via
StockStory
1 Small-Cap Stock on Our Watchlist and 2 We Question
May 04, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
3 Reasons to Sell COLL and 1 Stock to Buy Instead
April 29, 2026
Over the last six months, Collegium Pharmaceutical’s shares have sunk to $32.78, producing a disappointing 5.8% loss - a stark contrast to the S&P 500’s 4% g...
Via
StockStory
Topics
Stocks
Supply Chain
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
April 14, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via
StockStory
3 Cash-Producing Stocks Walking a Fine Line
April 10, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Via
StockStory
1 Value Stock on Our Buy List and 2 Facing Headwinds
April 06, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via
StockStory
Topics
ETFs
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
April 02, 2026
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
Via
StockStory
Topics
Economy
Stocks
World Trade
2 Profitable Stocks to Consider Right Now and 1 We Question
April 02, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
Topics
Bonds
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD
↗
March 30, 2026
This specialty pharma firm focused on pain management therapies reported a notable insider sale amid steady revenue and recent stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
March 25, 2026
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Collegium Pharmaceutical (NASDAQ:COLL) an...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million
↗
March 25, 2026
Collegium Pharmaceutical, a leader in abuse-deterrent pain therapies, saw its Chief Commercial Officer trim his stake by more than 40%.
Via
The Motley Fool
Topics
Regulatory Compliance
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
March 19, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know
March 16, 2026
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...
Via
StockStory
Topics
Economy
Stocks
3 Healthcare Stocks Walking a Fine Line
March 13, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz...
Via
StockStory
Collegium to Present New Real-World Data at PainConnect 2026
March 05, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
March 03, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
March 02, 2026
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today
February 27, 2026
Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell 6.7% in the afternoon session after the company reported fourth-quarter earnings and revenue that fell short of analysts'...
Via
StockStory
Collegium (COLL) Q4 2025 Earnings Call Transcript
↗
February 26, 2026
Collegium (COLL) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations
February 26, 2026
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 12.9% year on year to $205.4 million. The company’s full-year revenue...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
